Table 2.
Prefrontal dopamine release from compounds.
| Reference | Receptor activation | Compound alone | Dopamine increase (I) or decrease (D) | Compound with drug:increase (I) or decrease (D) compared to drug alone |
|---|---|---|---|---|
| Weikop et al. (2004) | Alpha2− | Idazoxan 1, 5 mg | I | I: venlafaxine + 200% |
| Gresch et al. (1995) | Idazoxan ic 0, 1–5 nM | I | ||
| Gobert and Millan (1999) | 1-PP | I: +90% | I: fluoxetine + 200% | |
| Tanda et al. (1996a) | Yohimbine | I | ||
| Millan et al. (2000) | Yohimbine | I | I: fluoxetine | |
| Millan et al. (2000) | Fluparoxan | I | I: fluoxetine | |
| Gobert et al. (1997b) | Atipamezole | I: +180% | I: duloxetine + 370% | |
| I fluoxetine + 170% | ||||
| Gobert et al. (1997b) | 1-PP 2, 5 mg | I: +90% | I: duloxetine + 600% | |
| Gobert et al. (1998) | RX821,002 | I: +73% | ||
| Gobert et al. (1998) | BRL44408 | I: +85% | ||
| Gresch et al. (1995) | Alpha 2+ | Clonidine 0, 2 mg | D | D: fluoxetine/buspirone |
| Tanda et al. (1996a) | Clonidine | D | ||
| Devoto et al. (2004) | Clonidine 0, 15 mg ip | D: mirtazapine | ||
| Gobert et al. (1997b) | S 18616 | D: −51% | ||
| Gobert et al. (1998) | Dexmedetomidine | D: −45% | ||
| Gobert et al. (1998) | Guanabenz | D: −50% | ||
| Gobert and Millan (1999) | S18616 | D: fluoxetine/buspirone | ||
| Tanda et al. (1996a) | 5HT2− | Ritanserine 1 mg | No I | I: yohimbine |
| Gobert et al. (2000) | 5HT2A | No I | ||
| MDL100907 | ||||
| Gobertet al. (2000) | 5HT2C/B | I | ||
| SB206553 | ||||
| Gobert et al. (2000) | 5HT2C | I | ||
| SB 242084 | ||||
| Gobert et al. (2000) | 5HT2B | No I | ||
| SB204741 | ||||
| Millan (1998) | 5HT2C– | I | ||
| SB 242084 | ||||
| Millan (1998) | 5HT2+ | 5HT2C+ | D | |
| Ro600175 | ||||
| Gobert et al. (2000) | 5HT2C+ | D | ||
| Ro600175 | ||||
| Gobert and Millan (1999) | 5HT1a+ | Pindolol | I | I: fluoxetine |
| I: duloxetine | ||||
| Millan and Gobert (1999) | Pindolol | I | ||
| Gobert et al. (1997a) | Buspirone 2, 5 mg | I: 100% | I: duloxetine + 550% | |
| I: Fluoxetine + 240% | ||||
| Tanda et al. (1994) | Buspirone 1 mg | I | ||
| Sakaue et al. (2000) | Buspirone | I | ||
| Gobert et al. (1997b) | Buspirone | I: +100% | I: fluoxetine + 300% | |
| Gobert et al. (1997b) | 8-OH-DPAT | I: +135% | I: fluoxetine | |
| Hughes et al. (2005) | 8-OH-DPAT 0, 3 mg | I | I: paroxetine + 400% | |
| Sakaue et al. (2000) | MKC242: 0, 3–1 mg | I | ||
| Invernizzi et al. (2003) | Flibanserin 10 mg | I: +63% | ||
| Gobert et al. (1998) | 8-OH-DPAT | I: +100% | ||
| Ago et al. (2005) | 5HT1a– | WAY100635 | D: sulpiride/fluvoxamine | |
| Valentini et al. (2005) | WAY100635 | D: imipramine | ||
| Invernizzi et al. (2003) | WAY100635 | D: flibanserin 10 mg | ||
| Nakayama et al. (2004) | WAY 100635 | D: mirtazapine | ||
| Gobert et al. (1998) | 5HT1b+ | GR46611 | No I | |
| Gobert et al. (1998) | 5HT1b− | GR127,935 | No I | |
| Kurata et al. (1996) | 5HT3+ | N-methylquipazine ic | I: dose dependent | |
| Nakayama (2002) | 5HT3− | Granisetron | D: paroxetine | |
| Tanda et al. (1995) | ICS 205930 ic and ip | D: fluoxetine | ||
| Kurata et al. (1996) | BRL46470A ic | D: dose dependent | ||
| Rivet et al. (1998) | 5HT | PCPA 20 mg | Despite PCPA, ADs induce DA increase: | |
| fluoxetine + 85%, duloxetine + 350%, | ||||
| desipramine + 290% | ||||
| mirtazapine + 300% fluoxetine + 202% | ||||
| citalopram + 211% | ||||
| Gobert et al. (1998) | D2+ | CGS15855A | D:−50% | |
| Gobert and Millan (1999) | D2− | Raclopride 16 mg/kg | I: +60% | |
| Gobert et al. (1998) | Raclopride | I:+60% | ||
| Ago et al. (2005) | Sulpiride 10 mg | No I | I: fluvoxamine 10 mg | |
| Ago et al. (2005) | Haloperidol 1 mg | I: fluvoxamine 10 mg | ||
| Carboni et al. (1990) | Haloperidol | I | I: desmethylimipramine | |
| I: oxaproptiline | ||||
| Nakamura et al. (2005) | Atypical Antipsy | Zotepine 10 mg | I | |
| Chotique | ||||
| D2– and 5HT2− | ||||
| Huang et al. (2006) | Risperidone 1 mg | I | I: citalopram 10 mg | |
| Zhang et al. (2000) | Olanzapine | I: fluoxetine +360% | ||
| I: sertraline | ||||
| Valentini et al. (2004) | Clozapine | +DOPA | ||
| Owen and Whitton (2006) | NMDA antagonist | Amantadine 40 mg/kg | No I | I: reboxetine |
| I: clomipramine | ||||
| I: paroxetine | ||||
| Toide (1990) | Amantadine 40 mg/kg | I: +16% | ||
| Owen and Whitton (2006) | Budipine 10 mg/kg | No I | I: reboxetine | |
| I: clomipramine | ||||
| I: paroxetine | ||||
| Spanagel (1994) | Memantine 5–20 mg | I: +50% | ||
| Hesselink (1999) | Memantine | No I | ||
| Shearman et al. (2006) | Memantine | I | ||
| Kitaichi et al. (2005) | Li | Lithium (7 days) | I: milnacipran | |
| Morissette and Paolo (1996) | LiCl 10 mEq | I | ||
| Watanabe (1999) | Hormones | Thyroid hormone T3 | I: desipramine | |
| Dazzi et al. (2007) | Estrogen: estrous cycle | I: Estrus | ||
| D: Proestrus | ||||
| Morissette and Paolo (1996) | Estrogen E2 | No I | I: Li | |
| Mizoguchi et al. (2008) | Adrenalectomy | D | ||
| Mizoguchi et al. (2004) | Adrenalectomy | D | ||
| Cortisol | I | |||
| Replacement | ||||
| Imperato et al. (1989) | Corticoïd | I |